In the second study, Adams and coworkers have analyzed 3,086 prostate cancers and have defined two hot spots in the forkhead domain involved in FOXA1 mutatrioins: WING2 (corresponding to about 50% of all mutations) and the DNA-contact residue R219 (about 5% of all mutations); WING2 mutations are observed in adenocarcinomas at all stages, while R219 mutations are enriched in neuroendocrine prostate cancers [733]. The gene discussed is FOXA1; the disease is prostate carcinoma.